Skip to content
MS
unreviewed

Lipoprotein lipase (LPL)

2 reactions · 1 pathways

Cofactors used

Clinical / pharmacological. LPL or apoC-II deficiency: familial chylomicronaemia (type I), pancreatitis

What it does, reaction by reaction

2 reactions

Lipoprotein Metabolism (Exogenous and Endogenous Pathways: chylomicrons, VLDL, LDL, HDL) Lipid Metabolism · Intestine, liver, plasma, capillary endothelium

step 5 Irreversible/directional

Chylomicron TAG + H2O → fatty acids + glycerol

Converts Chylomicron TAG H2O into Fatty acid Glycerol

› Notes

Endothelial LPL, activated by apoC-II and anchored by GPIHBP1, hydrolyzes core TAG. Insulin increases LPL activity in adipose tissue in the fed state, whereas cardiac/skeletal muscle LPL favors fatty-acid uptake according to local energy demand. Released fatty acids enter adipocytes for storage or muscle for oxidation; glycerol returns to liver.

step 10 Irreversible/directional

VLDL TAG + H2O → fatty acids + glycerol; VLDL → IDL

Converts VLDL TAG H2O into Fatty acid Glycerol VLDL

› Notes

LPL, activated by apoC-II, removes much of the VLDL TAG in capillary beds. ApoC-II is returned to HDL, and the particle becomes an intermediate-density lipoprotein (IDL; VLDL remnant) enriched in cholesteryl esters and retaining apoB-100 and apoE.

Showing all 2 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Lipoprotein Metabolism (Exogenous and Endogenous Pathways: chylomicrons, VLDL, LDL, HDL)

Accelerated by

ApoC-II; GPIHBP1-mediated endothelial presentation; ANGPTL8 in the fed state favors adipose LPL

Inhibited by

ApoC-III; ANGPTL3/ANGPTL4 (tissue/context dependent)

Hormonal control

Insulin increases adipose LPL after feeding; fasting shifts relative LPL activity toward oxidative tissues

Recent literature

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Autosomal dominant gain-of-function mutations in LCP1 cause a syndromic neutropenia and immunodeficiency.

    Yu L, Zhou B, Liu W, Li W, Wei Q, Zhang Y, Li C, Li W, Li Y, Li G, Sun G, Gan R, Chen R, Zhang W, Zeng A, Zha… · 2026-05-12

    open access unreviewed
  2. 2
  3. 3
    Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia.

    Bajaj A, McGuire M, Shugg S, Godin R, Underberg JA. · 2026-08-11

    open access unreviewed
  4. 4
  5. 5
  6. 6
    Efficacy of plasma exchange and exchange transfusion in the clinical management of severe hypertriglyceridemia in emergency.

    Stefanutti C, Zeppa G, Perrone G, Labbadia G, Galoppi P, Demarco V, Fornari E, Bordugo A, Santelia C, Manciop… · 2026-09-12

    open access unreviewed
  7. 7
    Targeting the gut-bone axis in osteoporosis: probiotic interventions and other microbiota-based therapeutic strategies.

    Zhao K, Zhang Z, Tang Z, Man X, Liu J, Feng R, Li K, Jiang Y, Li T. · 2026-09-17

    open access unreviewed
  8. 8
    Phloretin as a functional feed bioactive in livestock: Biological role, biosynthesis, and practical applications.

    Areb E, Zhu Q, Han L, Pan C, Li W, Lan X. · 2026-07-25

    open access unreviewed
  9. 9
  10. 10

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.